Inventor · disambiguated record
Gerhard Zugmaier
Also filed as: ZUGMAIER GERHARD
13 granted patents·10 pending applications·132 citations·filing 2006–2025
91Inventor score
Top patents by PatentIndex Score
23 records- 0195US7700299B2Method for predicting the response to a treatmentHOFFMANN LA ROCHE·Filed 2006·Granted Apr 20, 2010·54 cites·11 claims
- 0291US8840888B2Dosage regimen for administering a CD19XCD3 bispecific antibodyNAGORSEN DIRK·Filed 2010·Granted Sep 23, 2014·23 cites·34 claims
- 0390US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 0489US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 0589US10662243B2Dosage regimen for administering a CD19XCD3 bispecific antibodyAMGEN RES MUNICH GMBH·Filed 2014·Granted May 26, 2020·6 cites·20 claims
- 0687US11597766B2Treatment of acute lymphoblastic leukemiaAMGEN RES MUNICH GMBH·Filed 2018·Granted Mar 7, 2023·8 cites·21 claims
- 0784US10696744B2Means and methods for treating DLBCLAMGEN RES MUNICH GMBH·Filed 2015·Granted Jun 30, 2020·3 cites·13 claims
- 0881US9192665B2Means and methods for treating DLBCLZUGMAIER GERHARD·Filed 2011·Granted Nov 24, 2015·7 cites·19 claims
- 0979US10130638B2Prevention of adverse effects caused by CD3 specific binding domainsZUGMAIER GERHARD·Filed 2011·Granted Nov 20, 2018·5 cites·12 claims
- 1078US9486475B2PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 8, 2016·4 cites·14 claims
- 1169US11053318B2Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemiaAMGEN RES MUNICH GMBH·Filed 2017·Granted Jul 6, 2021·1 cites·5 claims
- 1269US2024109964A1Treatment of acute lymphoblastic leukemiaAMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1369US2023235053A1Treatment of pediatric acute lymphoblastic leukemiaAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 1462US2025282864A1Subcutaneous administration of cd19-binding t cell engagersAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 1560US2011262440A1Treatment of pediatric acute lymphoblastic leukemiaMICROMET AG·Filed 2009·Application pending·0 cites
- 1659US2010112603A1Method for predicting the response to a treatmentMOECKS JOACHIM·Filed 2009·Application pending·0 cites
- 1757US2021284732A1Dosing regimen for bcma-cd3 bispecific antibodiesAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 1857US2013323247A1Treatment of acute lymphoblastic leukemiaZUGMAIER GERHARD·Filed 2009·Application pending·0 cites
- 1953US11633408B2Prevention of adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2018·Granted Apr 25, 2023·0 cites·16 claims
- 2053US2025154255A1DOSING REGIMEN FOR BCMAx-CD3 ANTIBODIES CONSTRUCTSAMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 2149US2024197989A1Systems for out-patient treatment of a patient, and related methodsAMGEN INC·Filed 2022·Application pending·0 cites
- 2244US11079381B2Risk-stratification of B-precursor acute lymphoblastic leukemia patientsAMGEN RES MUNICH GMBH·Filed 2015·Granted Aug 3, 2021·0 cites·8 claims
- 2343US2022204620A1Means and methods for treating burkitt lymphoma or leukemiaAMGEN RES MUNICH GMBH·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →